Compare CarMax, Inc (KMX) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CarMax, Inc vs Tilray Brands Inc — how do they compare? CarMax, Inc trades at $52.61 (market cap $7.64B), while Tilray Brands Inc trades at $3.54 (market cap $530.54M). The key difference: CarMax, Inc is far larger — about 14.4× Tilray Brands Inc's market cap, and CarMax, Inc is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold CarMax, Inc for 49 Days and Tilray Brands Inc for 31 Days on average.
| KMX | TLRY | |
|---|---|---|
Market Cap | $7.64B | $530.54M |
Volume | 3,610,116 | 9,099,075 |
Sector | Consumer Cyclical | Health |
52-Week High | $64.22 | $17.20 |
52-Week Low | $30.88 | $3.54 |
Typical Hold Time | 49 Days | 31 Days |
Enterprise Value | $25.34B | $684.46M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CarMax (KMX) trades at $53.79, up 0.96% with recent earnings beats driving positive momentum. The stock shows bearish technical signals but strong fundamental improvements with Q2 2026 EPS of $1.16 beating estimates by 58%. Revenue grew 19.5% to $7.9 billion in the latest quarter, while the company's Shift into GEAR strategy shows early success. Valuation metrics remain reasonable with P/E of 25.37 and P/S of 0.28, though net margins remain thin at 1.06%.
KMX presents a turnaround story with improving operational execution but faces margin pressure and high debt levels. The consensus price target of $58.89 suggests 9.5% upside potential, though analyst sentiment remains cautious with 62% hold ratings. Key risks include used car market volatility and interest rate sensitivity, while catalysts include continued execution of the growth strategy and potential share buybacks.
TLRY trades at $3.59, down 3.36% on the day and near 52-week lows, with a bearish technical signal. The company reported revenue of $821.31M for 2025 but posted a net loss of -$2.19B, missing earnings expectations for four consecutive quarters. While analyst consensus shows 70% hold ratings, the stock faces significant profitability challenges with negative margins and cash flow concerns despite some revenue growth projections.
The outlook remains challenging with persistent losses and negative cash flow, though the stock trades at discounted valuation multiples. Key risks include ongoing profitability struggles and cannabis regulatory uncertainty. Potential catalysts include upcoming Q1 2027 earnings on October 8, 2026, and potential marijuana reform developments that could benefit the company's positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
